^
    1d
    MCC-20963: Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (clinicaltrials.gov)
    P2, N=25, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Inrebic (fedratinib)
    2d
    A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants. (clinicaltrials.gov)
    P1, N=64, Active, not recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    2d
    A Study of Ruxolitinib in Patients With Graft-Versus Host Disease (clinicaltrials.gov)
    P=N/A, N=395, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib)
    2d
    Fibrotic marrow limiting morphologic classification in MDS/MPN with SF3B1 mutation and thrombocytosis: diagnostic implications under the ICC 2022 framework. (PubMed, Virchows Arch)
    After ruxolitinib therapy, he later developed leukocytosis and 2% circulating blasts. Repeat marrow demonstrated ≥ 15% ring sideroblasts. Retrospectively, the initial biopsy fulfills ICC 2022 criteria for MDS/MPN-SF3B1-T, highlighting the diagnostic value of genetics-integrated classification in fibrotic marrows.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1)
    |
    SF3B1 mutation • NRAS G12
    |
    Jakafi (ruxolitinib)
    2d
    Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease (clinicaltrials.gov)
    P4, N=50, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Nov 2029 --> May 2029
    Trial primary completion date
    |
    Jakafi (ruxolitinib)
    3d
    Temozolomide and ruxolitinib combination modulates miRNA-associated regulatory networks in glioblastoma stem cells. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Overall, our findings suggest that TMZ may induce oncogenic miRNA expression as part of an adaptive response, while ruxolitinib may counteract this effect. Targeting miRNA-mediated regulatory networks in combination with pathway inhibition may represent a promising strategy to overcome therapeutic resistance in glioblastoma.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • BCL2L11 (BCL2 Like 11) • MIR221 (MicroRNA 221) • MIR19A (MicroRNA 19a)
    |
    temozolomide • Jakafi (ruxolitinib)
    5d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    5d
    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P2, N=330, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Oct 2026 --> Jun 2027
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    ALK positive
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    5d
    A Phase Ib/II Study of HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (clinicaltrials.gov)
    P1/2, N=156, Not yet recruiting, Hangzhou Highlightll Pharmaceutical Co., Ltd
    New P1/2 trial
    6d
    Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma (clinicaltrials.gov)
    P1, N=60, Completed, Case Comprehensive Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    temozolomide • Jakafi (ruxolitinib)
    6d
    A systematic evaluation of the efficacy and safety of entrectinib in anaplastic thyroid carcinoma. (PubMed, Gene)
    Knockdown of NTRK1, which encodes TrkA, reduced cell viability and sensitized ATC cells to paclitaxel. Entrectinib was well tolerated at the administered dose, with no significant changes in body weight and serum biochemical markers. Collectively, these findings identify TrkA as a potential therapeutic target in ATC and support further investigation of entrectinib-based combination strategies to improve ATC treatment outcomes.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    Rozlytrek (entrectinib) • paclitaxel
    6d
    Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study. (PubMed, Hematology)
    Treatment strategies included supportive care, interferon, hydroxyurea, and ruxolitinib. PMF and SMF demonstrate distinct clinical phenotypes despite sharing bone marrow fibrosis as a common endpoint. The mutational landscape highlights the genetic heterogeneity of MF and underscores the importance of integrating clinical, pathological, and molecular information to improve disease characterization and guide individualized management.
    Retrospective data • Journal
    |
    JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CALR (Calreticulin)
    |
    ASXL1 mutation
    |
    Jakafi (ruxolitinib) • hydroxyurea